SEC EDGARSEP 41 min read$ILMN

Meister Keith A. sold $57.2M of ILMN (indirect holdings)

Meister Keith A. sold 263,560 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $217.03 ($213.20–$221.55, $57.20M total) across 12 trades over 2026-09-02 to 2026-09-04.

Original reporting

SEC EDGAR · Meister Keith A.

Published Sep 4, 2026, 10:43 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Sep 4, 2026, 10:47 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$ILMN

Bearish

high confidence

Mentioned

$ILMN

Relevance

8/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNBearishMed

Why it matters

The $57.2M sale is the first public disclosure of this insider activity, providing new data for traders.

Market read

First‑report insider sale of significant size; may influence short‑term price action and sentiment in the biotech sector.

What to watch

The sale was executed via multiple small trades and may reflect personal tax planning rather than company outlook.

Relevance 8/10Novelty 8/10Timing: post‑market filing on 2026‑09‑04

Background

SEC Form 4 filing discloses insider transactions; director sales are monitored for signals about company health.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNBearishHigh confidence

Context

Director Meister Keith A. sold 263,560 shares worth $57.2M, reducing his stake to 770,350 shares.

Expected impact

Short-term price dip expected as market digests the $57M sale.

Evidence & confidence

The sale size is material for a mid‑cap biotech and is disclosed for the first time via a Form 4 filing.

Market effects

Sector

May raise concerns for other diagnostics and genomics firms as insider confidence is questioned.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond Illumina shareholders.

Counterpoint

What could challenge this read

Insider sales can be routine liquidity events; the market may overreact to the headline.

Key entities

Company
Illumina, Inc.
US‑listed genomics and diagnostics firm (ticker ILMN).
Individual
Meister Keith A.
Director of Illumina who executed the share sale.

Read at source ← All news

SEP 4

$BEHigh

Bloom Energy, Illumina, and Everpure set to join S&P 500 in quarterly rebalance

Bloom Energy (BE), Illumina (ILMN), and Everpure (EVR) will join the S&P 500, replacing Molson Coors (TAP), The Trade Desk (TTD), and Builders FirstSource (BLDR). BE rose 7.5%, ILMN 2%, and EVR 2.2% after-hours. Changes take effect Sept. 21, with affected companies also moving between mid-cap and small-cap indices.

investing.com2 min

SEP 2

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

etfdb.com3 min

AUG 27

$ILMNLowAI 8/10

Meister Keith A. sold $85.2M of ILMN (indirect holdings)

Meister Keith A. sold 375,941 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $226.74 ($224.72–$231.23, $85.24M total) across 13 trades over 2026-08-25 to 2026-08-27.

SEC EDGAR1 min

AUG 26

$ILMNMed

Does Illumina’s (ILMN) New Credit Line Quietly Redefine Its Risk Buffer and Strategic Flexibility?

Illumina (ILMN) secured a new $1.00 billion revolving credit facility, replacing its 2023 agreement. The facility offers variable-rate borrowing and covenant limits, with no amounts drawn initially. This enhances liquidity and financial flexibility amid stronger revenue and earnings guidance. The company's focus remains on clinical sequencing, with risks including competition, China exposure, and research funding. Analysts' revenue growth expectations vary, with some projecting 5.2% annual growt

simplywall.st2 min

AUG 25

$ILMNMedAI 8/10

Illumina Stock Is Up 82% in Six Months. The Street’s Target Still Trails It.

Illumina (ILMN) stock has risen 82% in six months, closing at $223.22 on August 24. The surge follows three quarters of raised guidance due to strong clinical sequencing demand. Analysts' average price target is $199, 11% below the current price. TIKR's model values the stock at $259 by late 2030, implying a 16% total return. Potential S&P 500 inclusion adds speculative momentum.

tikr.com2 min